A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...

Estrella Immunopharma ( ($ESLA) ) has shared an announcement. On May 30, 2025, Estrella Immunopharma entered into a securities purchase agreement ...

HemOnc Today hosted its fourth Disruptive Innovators Awards ceremony, crowning nine new winners at ASCO Annual Meeting. Co-hosted by Shikha Jain, MD, FACP, founder of Women in Medicine, and Ed S. Kim, ...

The spring meeting of the Irish Society for Rheumatology brought together experts from across Ireland and the UK to highlight ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...

In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of ...

Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed ...